Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute of Mental Health (NIMH)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Inflammation|Brain Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 000674-M | P1 |
Terminated |
Brain Diseases|Inflammation |
2023-05-09 |
2024-07-10 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|